- Home
- LEGH vs LBRX Comparison
LEGH vs LBRX Comparison
Compare LEGH & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGH | LBRX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.2M | 602.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | LEGH | LBRX |
|---|---|---|
| Price | $19.35 | $24.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $25.00 | ★ $49.00 |
| AVG Volume (30 Days) | 88.4K | ★ 187.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $184,191,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.07 | N/A |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.84 | $13.40 |
| 52 Week High | $29.45 | $25.60 |
Technical Indicators
Market Signals| Indicator | LEGH | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 58.07 |
| Support Level | $18.93 | $22.34 |
| Resistance Level | $22.69 | N/A |
| Average True Range (ATR) | 0.69 | 1.21 |
| MACD | -0.25 | -0.05 |
| Stochastic Oscillator | 16.67 | 76.47 |
Price Performance
Historical ComparisonAbout LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.